News
Q2 2025 Earnings Call Transcript August 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS ...
SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding ...
Company to host public (L)earnings call on August 5th at 8:00 am ET / 6:00 am MT / 1:00 pm BSTSalt Lake City, UT, July 29, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage ...
AI-led drug for chronic lung disease set to enter phase 3 clinical trials, though experts remain divided on AI's impact in ...
Artificial intelligence is advancing at a speed that’s difficult to comprehend. To describe this phenomenon, insiders have begun referencing what some call “OpenAI’s Law”—a modern parallel to Moore’s ...
Professors Juan Tu, Dong Zhang, Jingning Zhu, and Academician Ning Gu from Nanjing University developed an ultrafast ultrasound localization microscopy algorithm combining velocity constraints and ...
Zhang Xi, deputy dean and professor at the School of Cyberspace Security at the Beijing University of Posts and ...
Building public trust is essential for brands to cut through the noise, and storytelling is one of the most effective ways to do so. We live in an innovation age, and innovation leads to ...
Will AI take over the world? Nobody knows for sure, but we examine the most compelling arguments from both sides of the debate.
Recursion Pharmaceuticals (NASDAQ:RXRX) stock is one of those lesser-known mid-cap biotech plays that investors may be ...
In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results